ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $11M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 7 closing their positions.
16% more capital invested
Capital invested by funds: $9.54M → $11M (+$1.5M)
8.82% more ownership
Funds ownership: 32.08% → 40.9% (+8.8%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
20% less funds holding
Funds holding: 25 → 20 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$4.59M |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
+$345K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$271K |
| 4 |
LPL Financial
San Diego,
California
|
+$206K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$25.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$658K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$320K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$236K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$196K |
| 5 |
CA
CoreCap Advisors
Southfield,
Michigan
|
-$121K |
CNCR Hedge Fund Activity: Q1 2022 in Review
20 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2022, worth a combined $11M — up 16% from $9.54M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNCR and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was BCWM LLC, adding an estimated $4.59M. The largest seller was Goldman Sachs, exiting entirely with an estimated $658K sold.
- 20 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2022, down from 25 in Q4 2021.
- Funds reported $11M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2022, up 16% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2022 and 7 closed out, a net change of -5 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2022 was BCWM LLC, an estimated $4.59M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2022 was Goldman Sachs, an estimated $658K sold.
Based on aggregated 13F filings for Q1 2022.